Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates significantly across all major metrics: revenue was $23.0M vs. $24.9M expected, and GAAP EPS was -$0.07 vs. -$0.02 expected. The topline decline of 35% YoY was driven by the divestiture of non-core assets and the loss of high-margin license revenue due to reimbursement changes. Management subsequently lowered FY26 revenue guidance to $99M-$103M, below the prior range, citing biologics headwinds.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Xtant Med(XTNT) the Revenue is 23.03 M (-34.96%), Miss estimate;the EBIT is -9.169 M (-298.3%), Miss estimate;the EPS is -0.07 (-450%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.02B34.96%
0.02B29.75%
-0.00B5.21%
EBITMiss expectations
-0.01B298.29%
-0.00B141.97%
-0.01B156.32%
EPSMiss expectations
-0.07450.00%
-0.02200.00%
-0.0500250.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf